CPHI Profile
China Pharma Holdings, Inc. operates as a prominent developer, manufacturer, and distributor of both generic and branded pharmaceutical and biochemical products across the People's Republic of China. Specializing in products catered primarily to hospitals and private retailers, the company offers a diverse range of formulations including dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its extensive product portfolio addresses various medical needs, featuring treatments such as Cerebroprotein Hydrolysate for memory decline, Gastrodin for brain-related symptoms, and Bumetanide for edema diseases.
The company's offerings extend to therapeutic solutions like Roxithromycin for respiratory infections, Cefaclor for infections across different organ systems, and Andrographolide for upper respiratory tract infections. Additionally, China Pharma Holdings provides medications for cardiovascular ailments including Propylgallate and Ozagrel Sodium, addressing conditions such as cerebral thrombosis and coronary heart disease. Its product line also includes vitamins, growth factors, and food supplements, emphasizing a comprehensive approach to healthcare.
Headquartered in Haikou, China, the company was founded in 1993 and has expanded its market presence through a network of 16 sales offices and approximately 1,000 sales representatives. This expansive distribution network enables China Pharma Holdings to efficiently reach its customer base and deliver essential healthcare solutions nationwide. Committed to quality and innovation in the pharmaceutical sector, the company continues to enhance its product offerings while adhering to rigorous standards of manufacturing and distribution.
With a strategic focus on meeting the evolving healthcare needs of the Chinese market, China Pharma Holdings remains dedicated to advancing healthcare accessibility and improving patient outcomes. Through ongoing research and development initiatives and strategic partnerships, the company aims to strengthen its position as a leader in the pharmaceutical industry while contributing to the broader healthcare landscape in China.
|
